HER2陽性・測定可能病変を有さない進行再発胃癌に対するS-1＋cisplatin＋trastuzumab3週間サイクル併用療法第Ⅱ相試験（OGSG:1202, HERBIS-1B）

A Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

Five‑year outcomes of a phase II study of adjuvant chemotherapy with S‑1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002)

Phase II study of 5‑fluorouracil–leucovorin plus bevacizumab for chemotherapy‑naïve older or frail patients with metastatic colorectal cancer (OGSG 0802)

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

Adjuvant S-1+DTX for stage III gastric cancer its clinical power based on survival analysis from 2 phase II studies (OGSG0604, OGSG1002)

A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)

A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (HERBIS-4B / OGSG 1106)

An Intergroup phase III trial of Ramucirumab plus Irinotecan in Third or more line Beyond Progression after Ramucirumab for advanced Gastric Cancer (RINDBeRG trial)

Adjuvant S-1+DTX therapy for Stage III gastric cancer: survival analysis of the two phase II trials (OGSG0604, OGSG1002)